N/A N=58 Disease Management for Coronary Artery Patients
Patient Empowerment · Coronary Artery Disease
Primary: Compliance Questionnaire Scores of the Participants — 22.25; 22.53 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=39 Healthy Combine Study
Healthy
Primary: Change in Intact FGF23 — 1.001; 1.006; 1.009; 1.005 pg/ml — p=0.3738
N/A N=5,117 Periodontal Disease Prevention Study
Periodontitis
Primary: Percentage of Participants With Tooth Loss Over 16 Year Period — 16.4; 13.8; 22.1; 16.9 percentage of participants
N/A N=40 Clinical Validation Study for Noninvasive Cardiopulmonary Management Device
Cardiopulmonary Disease
Primary: Correlation Coefficient for Accuracy of Test Device vs Reference Device — 0.99; 0.95 Correlation Coefficient
N/A N=28 Rhode Island Diastolic Dysfunction - Heart Failure
Heart Failure · Cardiovascular Disease
Primary: Change From Baseline in Oxygen Consumption During Maximal Bike Exercise — 14.45; 14.18 mL/kg/min — p=0.823
Phase 1 N=88 Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Adverse Events — 2; 2; 2; 1 participants
N/A N=20 Healthy Patients & Effect of Antibiotics
Microbiota · Anti-bacterial Agents
Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants
Phase 2 N=61 Heart Rate Variability in Response to Metformin Challenge
Fibromyalgia · Mitochondrial Diseases · Movement Disorders
Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77
Phase 2 N=28 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
Atopic Dermatitis
Primary: The Number of Patients in the Study With HPA Axis Suppression — 8; 9 Participants
Phase 1 N=28 A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.
Liver Diseases · Hepatic Impairment
Primary: Plasma Maximum Concentration (Cmax) of Sisunatovir Following Administration of a Single Oral Dose — 81.25; 68.52; 73.85; 127.8 Nanograms/milliliter (ng/mL)
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Phase 2 N=3 Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants
N/A N=200 Urinalysis Results in Healthy Individuals
Asymptomatic Bacteriuria · Asymptomatic Pyuria
Primary: False Positive Urine — 6; 40 Participants
Phase 2 N=60 RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With Adverse Events — 0; 0; 2; 3 Participants
Phase 2 N=50 Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Percentage Change in Liver Fat Relative to Baseline Assessed by MRI-PDFF — 13.9; 8.4 percentage change in liver fat — p=0.585
N/A N=28 Chronic Liver Disease in Urea Cycle Disorders
Urea Cycle Disorder
Primary: Liver Stiffness as Measured by Shear Wave Elastography — 13; 14 Participants
Phase 1 N=12 Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects
Arthritis, Rheumatoid
Primary: Part 1: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL) 6 for LPS Arm — 2.4086; 0.2798…
Phase 2 N=18 An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters
Colonoscopy · Bowel Preparation
Primary: Maximum Observed Concentration (Cmax) — 717.0; 499.5; 560.2 µmol/L
N/A N=202 Weight Loss in Chronic Disease Patient Population
Overweight · Obesity · Diabetes
Primary: Change in Body Weight — -1.7; -.2; -4.3; -3.0 pounds — p=.296
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
Phase 4 N=54 The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
Type 2 Diabetes · Diabetes
Primary: Change in Fasting Plasma Glucose Concentration — 4.7; 0.0 mmol/l
N/A N=31 A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects
Healthy
Primary: Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) — 21.48 U/L
Phase 1 N=24 A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
Phase 2 N=16 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
Plaque Psoriasis
Primary: Proportion of Patients in the Study With HPA Axis Suppression — 1; 0; 10; 0 Participants
Phase 2 N=32 Effects of Metformin in a Non-Diabetic Patient Population
Inflammatory Response
Primary: Ex Vivo Cytokine Response of Peripheral Blood Mononucleocytes (PBMC) to Inflammatory Stimuli Compared to Baseline, Throughout Exposure, and Following Exposure to…
N/A N=168 An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
Crohn's Disease · Rheumatoid Arthritis · Psoriasis
Primary: Change From Baseline in WHODAS 2.0 Response Score at Month 6 Across All Indications — 7.9 units on a scale — p=< 0.001
N/A N=22 Immune Profile in Subjects With New Onset Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B…
Phase 1 N=48 Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid
Multi-drug Resistant Tuberculosis
Primary: Relative Bioavailability - Cmax — 2170; 1180; 1850; 1090 ng/mL — p=0.0001
Phase 2 N=1 JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
Kohlmeier Degos Disease With Neurologic Involvement · Kohlmeier-Degos Disease
Primary: Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib — 1; 0; 0 Participants
N/A N=183 Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants